Markets
Temporary Fix Keeps National Flood Insurance Operating, But Only Until Nov. 17
Real estate interests and insurance companies that administer National Flood Insurance Program policies are heaving a sigh of relief after Congress approved a last-minute deal to temporarily fund the ...
MGA Skyrisks Officially Launches With Investment, Capacity From Convex Group
Skyrisks Ltd., the London-based MGA and specialist in the advanced air mobility (AAM) sector, has officially launched with capacity and a cornerstone investment from Convex Group, the specialty ...
Progressive Nonrenews 100,000 Homeowner and Dwelling Fire Policies in Florida
Almost two years after Progressive Insurance announced it would stop renewing some homeowners policies in Florida, Flo and crew have dropped another 100,000 homeowner and landlord policies in the ...
Homeowners Unprepared for Non-Weather-Related Water Damage: Report
Homeowners lack preparedness for non-weather-related water damage, even though water damage ranks as the second most prevalent cause of insurance loss claims, according to The Hanover Insurance Group ...
AXIS and Stone Point Credit Launch Monarch Point Re, Raising Over $400M of Capital
AXIS Capital Holdings Ltd., together with its direct and indirect subsidiaries and branches, announced that it has partnered with Stone Point Credit Adviser LLC to launch Monarch Point Re, a newly ...
Class Action Against USAA; Failure to Pay Lessees Residual Value of Totaled Cars Alleged
A recently filed class action lawsuit in a California District Court accuses USAA General Indemnity Company of deceptive and unfair practice for failing to pay insureds the amount owed after leased ...
Workers Compensation: Waning Benefits From Decreasing Opioid Rxs
Workers compensation has been a profit juggernaut for the property/casualty insurance industry over the past several years. Underwriting profits from the workers comp line have accounted for the ...
The Legal Tensions of Collaboration and Competition in the Life Sciences Industry
Moderna's suit against Pfizer and partner BioNtech over alleged COVID-vaccine-related patent infringement — and the targets' countersuit — might suggest an abrupt return to business as usual ...